awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q28072254-9B33422E-C1C0-42A7-A15E-F08464BFB60A
Q28072254-9B33422E-C1C0-42A7-A15E-F08464BFB60A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28072254-9B33422E-C1C0-42A7-A15E-F08464BFB60A
Maximising the potential of AKT inhibitors as anti-cancer treatments
P2860
Q28072254-9B33422E-C1C0-42A7-A15E-F08464BFB60A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28072254-9B33422E-C1C0-42A7-A15E-F08464BFB60A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ffd227e0986d46e38bfa74a52403cd002a1d1e51
P2860
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.